---
abstract: ''
authors:
- Doshi, Krupa B
- Khan, Leila Zeinab
category: Case Study
clinical_significance: High
cme_credits: 0.0
doi: ''
evidence_level: ''
external_resources:
- title: PubMed Entry
  type: reference
  url: https://pubmed.ncbi.nlm.nih.gov/37983691/
file_path: 2023/11/should-bone-turnover-markers-be-used-routinely-to-monitor-or.md
issue: '5'
keywords:
- Bone Density Conservation Agents
- Administration, Oral
- Humans
- Bone Density
- Biomarkers
- Bone Remodeling
- Osteoporosis, Postmenopausal
- Osteoporosis
- Female
- Diphosphonates
last_updated: '2025-08-09'
mesh_terms:
- Humans
- Female
- Osteoporosis
- Diphosphonates
- Bone Remodeling
- Bone Density Conservation Agents
- Bone Density
- Osteoporosis, Postmenopausal
- Biomarkers
- Administration, Oral
- Medication Adherence
original_format: PubMed
pages: 442-443
patient_population: Adults
peer_reviewed: true
pmid: '37983691'
processed_date: '2025-08-09'
publication_date: '2023-11-01'
pubmed_enriched: true
pubmed_enriched_date: '2025-08-09'
reading_time_minutes: 1
source: American family physician
specialties:
- Family Medicine
status: processed
tags:
- editorial
- family-practice
- clinical-medicine
- pubmed-enhanced
title: 'Should Bone Turnover Markers Be Used Routinely to Monitor Oral Bisphosphonate
  Osteoporosis Therapy? Yes: Measuring Adherence and Effectiveness of Therapy Benefits
  Patients.'
topics:
- Family Medicine
volume: '108'
publication_types: &id001
- Editorial
pubmed_content_enriched: true
pubmed_full_data:
  pmid: '37983691'
  title: 'Should Bone Turnover Markers Be Used Routinely to Monitor Oral Bisphosphonate
    Osteoporosis Therapy? Yes: Measuring Adherence and Effectiveness of Therapy Benefits
    Patients.'
  authors:
  - last_name: Doshi
    fore_name: Krupa B
    initials: KB
    affiliation: Mayo Clinic, Scottsdale, Arizona.
  - last_name: Khan
    fore_name: Leila Zeinab
    initials: LZ
    affiliation: Cleveland Clinic Foundation, Cleveland, Ohio.
  journal_info:
    title: American family physician
    iso_abbreviation: Am Fam Physician
    volume: '108'
    issue: '5'
  publication_info:
    year: '2023'
    month: '11'
    full_date: '2023-11-01'
  article_ids: {}
  mesh_terms:
  - descriptor: Humans
    major_topic: false
  - descriptor: Female
    major_topic: false
  - descriptor: Osteoporosis
    major_topic: true
    qualifiers:
    - qualifier: diagnosis
      major_topic: false
    - qualifier: drug therapy
      major_topic: false
  - descriptor: Diphosphonates
    major_topic: false
    qualifiers:
    - qualifier: therapeutic use
      major_topic: false
  - descriptor: Bone Remodeling
    major_topic: false
  - descriptor: Bone Density Conservation Agents
    major_topic: true
    qualifiers:
    - qualifier: therapeutic use
      major_topic: false
  - descriptor: Bone Density
    major_topic: false
  - descriptor: Osteoporosis, Postmenopausal
    major_topic: true
    qualifiers:
    - qualifier: drug therapy
      major_topic: false
  - descriptor: Biomarkers
    major_topic: false
  - descriptor: Administration, Oral
    major_topic: false
  - descriptor: Medication Adherence
    major_topic: false
  publication_types: *id001
---

# Should Bone Turnover Markers Be Used Routinely to Monitor Oral Bisphosphonate Osteoporosis Therapy? Yes: Measuring Adherence and Effectiveness of Therapy Benefits Patients.

**Authors:** Doshi, Krupa B, Khan, Leila Zeinab

**Published in:** American family physician | Vol. 108, No. 5 | 2023-11-01

**Links:** [PubMed Entry](https://pubmed.ncbi.nlm.nih.gov/37983691/)

## Clinical Information

**Population:** Adults | **Clinical Significance:** High

## Topics & Specialties

**Specialties:** Family Medicine

**Topics:** Family Medicine

## MeSH Terms

Humans, Female, Osteoporosis, Diphosphonates, Bone Remodeling, Bone Density Conservation Agents, Bone Density, Osteoporosis, Postmenopausal, Biomarkers, Administration, Oral, Medication Adherence

## Article Content

# Should Bone Turnover Markers Be Used Routinely to Monitor Oral Bisphosphonate Osteoporosis Therapy? Yes: Measuring Adherence and Effectiveness of Therapy Benefits Patients.

**Authors:** Doshi, Krupa B, Khan, Leila Zeinab

**Published in:** American family physician | Vol. 108, No. 5 | 2023-11-01

**Links:** [PubMed](https://pubmed.ncbi.nlm.nih.gov/37983691/)

## Clinical Information

**Population:** Adults | **Clinical Significance:** High

## Topics & Specialties

**Specialties:** Family Medicine

**Topics:** Family Medicine

## MeSH Terms

Humans, Female, Osteoporosis, Diphosphonates, Bone Remodeling, Bone Density Conservation Agents, Bone Density, Osteoporosis, Postmenopausal, Biomarkers, Administration, Oral, Medication Adherence

## Article Content

*Full article content to be extracted and formatted from source material.*

## Additional Resources

- [PubMed Entry](https://pubmed.ncbi.nlm.nih.gov/37983691/) (reference)

---

*Processed: 2025-07-30* | *PubMed Enhanced: 2025-07-30*

## Additional Resources

- [PubMed Entry](https://pubmed.ncbi.nlm.nih.gov/37983691/) (reference)

---

*Processed: 2025-08-09* | *PubMed Enhanced: 2025-07-30*
